Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

UK: Cannabis could be getting the NICE treatment

Surgery Door

Monday 18 Feb 2002

---
Cannabis-based medicines could be available on the NHS by 2004, but only if
the government decides to refer them to its medicines advisory board.

The Department of Health on Monday (18/02/02) began a consultation to
determine the next batch of treatments to be appraised by the National
Institute for Clinical Excellence (NICE) for availability on the NHS. The
pharmaceutical industry, professional bodies and patient groups are all
being invited to participate in the month-long consultation.

Among the drugs being considered for referral to NICE are cannabinoids for
pain relief in multiple sclerosis (MS) patients.

Ongoing trials into the pain-relieving properties of cannabis are due to be
completed by the end of the year. The Medical Research Council is funding
two trials, one at Derriford Hospital in Plymouth and another at
Hammersmith Hospital in London.

The drugs company GW Pharmaceuticals is also conducting its own clinical
trials on cannabis-based medicines for the treatment of MS pain, cancer
pain and other forms of nerve pain.

Early results are believed to be positive but it is thought a decision on
whether to license one or more cannabis-derived products will be made by
2004-05.

Health Minister Lord Hunt said NICE would use the trial results in its
appraisal of the drugs.

He said, "If these pharmaceuticals are licensed for medical use, it is of
critical importance that NICE guidance is in place for the clinicians who
will have to make important decisions about their use."

Dr Geoffrey Guy, executive chairman of GW Pharmaceuticals, said the
announcement was a positive move by the government.

"Recommendation by NICE would further smooth the way for our cannabis-based
medicines to be available nationwide to NHS patients on prescription, if
our current trials are successful," he said.

Other treatments being considered as part of the consultation include
hormonal treatments for early breast cancer, new treatments for Alzheimer's
disease and other forms of dementia, and pegylated interferons for hepatitis C.

 

 

 

After you have finished reading this article you can click here to go back.




This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!